Who we are
PrimeCell Therapeutics is a global hi-tech company focused on the area of regenerative medicine, tissue engineering and tissue banking. Its unique know-how enables PrimeCell Therapeutics to develop and produce Advanced Therapy Medical Products (ATMPs) which are designed to increase the quality of human life.
PrimeCell Therapeutics is recognised as a regional leader within the sphere of Advanced Therapy, cell therapy and tissue engineering. PrimeCell Therapeutics uses proprietary technologies to combine scaffolds with autologous and allogeneic human body cells to produce ATMPs.
PrimeCell Therapeutics collaborates with top-notch scientific institutions in a bid to put scientific research results into clinical practice. Our clients comprise of top-class medical facilities and healthcare centres across countries, such as Germany, Slovakia, the Netherlands, Portugal, the US, South Korea, etc. In the area of research, development and clinical testing, PrimeCell Therapeutics co-operates with over twenty scientific institutions, universities and university hospitals. Altogether, PrimeCell Therapeutics combines highly qualified, world-renowned experts in the area of medicine, biotechnology, material engineering with medical management.
Our key cell therapy product is NTC chodrograft®, the first and best-in-class product for surgical orthopaedic indications. NTC chodrograft® has been in development for the last twelve years and to-date we have treated approximately four hundred patients.
In the field of tissue engineering, PrimeCell Therapeutics is known as one of the most competitive producers on the European and global market and it is also the member of the European Association of Tissue Banks.
PrimeCell Therapeutics is regarded as a regional leader in the area of cell industrialisation and tissue processing. The PrimeCell Therapeutics cord blood bank is the largest and the most innovative cord blood bank in the Czech Republic, which is located in Brno in National Cell and Tissue Centre.
PrimeCell Therapeutics currently operates two production facilities dedicated to cell and tissue processing. Third state-of-the-art research and manufacturing facility is expected to be finished in 2013.